• linkedin
  • Increase Font
  • Sharebar

    Senate to conduct investigation into Rx drug pricing


    The U.S. Senate will conduct a bipartisan investigation into pharmaceutical drug prices following recent public and political outrage over drastic price increases for certain drugs.

    The Senate Special Committee on Aging has scheduled a hearing for December 9, 2015. The committee has sent letters to Valeant Pharmaceuticals, Turing Pharmaceuticals, Retrophin, and Rodelis Therapeutics requesting specific information.

    Editor’s Choice: Rising Rx prices front and center in presidential campaign

    “Some of the recent actions we’ve seen in the pharmaceutical industry—with corporate acquisitions followed by dramatic increases in the prices of pre-existing drugs—have looked like little more than price gouging,” U.S. Senator Claire McCaskill, (D-Mo.) stated in a release.

    “We need to get to the bottom of why we’re seeing huge spikes in drug prices that seemingly have no relationship to research and development costs. I’m proud to help lead this bipartisan investigation so that we can find some answers the public wants and deserves,” he added.

    McCaskill and U.S. Senator Susan Collins (R-Maine), another member of Senate Special Committee on Aging, said the hearing would focus on drugs that have recently had significant price hikes.

    “We seek your cooperation with this investigation so that the Committee may better understand drug pricing and related regulatory and public policy concerns,” the letter to Turing Pharmaceuticals CEO Martin Shkreli stated. “In particular, the Committee wishes to learn more about Turing Pharmaceuticals’ recent acquisition of the rights to sell Daraprim, a drug used to treat and prevent infections, from Impax Laboratories and Turing’s subsequent decision to increase the price of Daraprim from $13.50 to $750 [per tablet].”

    Mark Lowery, Editor
    Mark Lowery an Editor for Drug Topics magazine.

    1 Comment

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • RandallDavis
      Would the 50% kickback of drug cost dictated by the "Affordable Care Act" have anything to do with the prices doubling? This tells me that these idiotic Senators have not read the ACA or know what is in it. I am appalled that the author missed this fact too. Government required a kickback, and the price increases. Hmmm this is not rocket science.